1-[3-fluoro-4-(7-hydroxy-6-methoxyquinolin-4-yloxy)phenyl]-3-phenylacetylurea | 479687-64-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[3-fluoro-4-(7-hydroxy-6-methoxyquinolin-4-yloxy)phenyl]-3-phenylacetylurea
• 英文别名: N-{4-[(7-hydroxy-6-methoxy-4-quinolyl)oxy]-3-fluorophenyl}-N'-(2-phenylacetyl)urea；N-[[3-fluoro-4-(7-hydroxy-6-methoxyquinolin-4-yl)oxyphenyl]carbamoyl]-2-phenylacetamide
• CAS: 479687-64-4
• 化学式: C₂₅H₂₀FN₃O₅
• 分子量: 461.449
• InChiKey: XULMREJEBFJUQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-[3-fluoro-4-(7-hydroxy-6-methoxyquinolin-4-yloxy)phenyl]-3-phenylacetylurea 、 1-溴-3-氯丙烷 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 5.0h， 以78%的产率得到1-{4-[7-(3-chloro-propoxy)-6-methoxyquinolin-4-yloxy]-3-fluorophenyl}-3-phenylacetylurea
  参考文献：
  名称：

  QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME

  摘要：

  公开号：

  EP1411046B1
• 作为产物：
  描述：

  N-(4-{[7-(benzyloxy)-6-methoxy-4-quinolyl]oxy}-3-fluorophenyl)-N'-(2-phenylacetyl)urea 在 palladium hydroxide on carbon 氢气 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 10.0h， 以85%的产率得到1-[3-fluoro-4-(7-hydroxy-6-methoxyquinolin-4-yloxy)phenyl]-3-phenylacetylurea
  参考文献：
  名称：

  QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME

  摘要：

  公开号：

  EP1411046B1

文献信息

• Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
  申请人：——

  公开号：US20040242603A1

  公开（公告）日：2004-12-02

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: 1 wherein X=CH or N; Z=O or S; L=O or S; M=CR 10 R 11 , wherein R 10 and R 11 =H, alkyl, or alkoxy, NR 12 wherein R 12 =H or alkyl; R 1 , R 2 , and R 3 =H or optionally substituted alkoxy; R 4 =H; R 5-8 =H, halogen, alkoxy or the like; and R 9 =alkyl optionally substituted by —R 14 , -T-R 15 , or —NR 16 R 17 wherein T=O, S, or NH; R 14 =an optionally substituted carbocyclic or heterocyclic ring; and R 15-17 =alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR 18 R 19 wherein R 18 and R 19 =H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目标是提供具有强效抗肿瘤活性的化合物。本发明的化合物由以下式子（I）或其药学上可接受的盐或溶剂表示：1其中X = CH或N；Z = O或S；L = O或S；M = CR10R11，其中R10和R11 = H，烷基或烷氧基，NR12，其中R12 = H或烷基；R1、R2和R3 = H或可选取代烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；以及R9 = 烷基，可选取代-R14、-T-R15或-NR16R17，其中T = O、S或NH；R14 = 可选取代的碳环或杂环；R15-17 = 烷基或可选取代的碳环或杂环，或-NR18R19，其中R18和R19 = H、可选取代的烷基或可选取代的碳环或杂环，或可选取代的碳环或杂环。
• QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1411046A1

  公开（公告）日：2004-04-21

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X = CH or N; Z = O or S; L = O or S; M = CR10R11, wherein R10 and R11 = H, alkyl, or alkoxy, NR12 wherein R12 = H or alkyl; R1, R2, and R3 = H or optionally substituted alkoxy; R4 = H; R5-8 = H, halogen, alkoxy or the like; and R9 = alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T = O, S, or NH; R14 = an optionally substituted carbocyclic or heterocyclic ring; and R15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 = H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目的是提供具有强效抗肿瘤活性的化合物。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X = CH 或 N；Z = O 或 S；L = O 或 S；M = CR10R11，其中 R10 和 R11 = H、烷基或烷氧基，NR12，其中 R12 = H 或烷基；R1、R2 和 R3 = H 或任选取代的烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；R9 = 任选被 -R14、-T-R15 或 -NR16R17 取代的烷基，其中 T = O、S 或 NH；R14 = 任选取代的碳环或杂环；以及 R15-17 = 烷基或任选取代的碳环或杂环，或 -NR18R19 其中 R18 和 R19 = H、任选取代的烷基或任选取代的碳环或杂环，或任选取代的碳环或杂环。
• Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
  申请人：Kirin Pharma Kabushiki Kaisha

  公开号：EP2088141A2

  公开（公告）日：2009-08-12

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X = CH or N; Z = O or S; L = O or S; M = CR10R11, wherein R10 and E11 = H, alkyl, or alkoxy, NR12 wherein R12 = H or alkyl; R1, R2, and R3 = H or optionally substituted alkoxy; R4 = H; R5-8 = H, halogen, alkoxy or the like; and R9 = alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T = O, S, or NH; R14 = an optionally substituted carbocyclic or heterocyclic ring; and R15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 = H, optionally substituted alkyl, or an optionally substituted carbocyclic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目的是提供具有强效抗肿瘤活性的化合物。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X = CH 或 N；Z = O 或 S；L = O 或 S；M = CR10R11，其中 R10 和 E11 = H、烷基或烷氧基，NR12，其中 R12 = H 或烷基；R1、R2 和 R3 = H 或任选取代的烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；R9 = 任选被 -R14、-T-R15 或 -NR16R17 取代的烷基，其中 T = O、S 或 NH；R14 = 任选取代的碳环或杂环；以及 R15-17 = 烷基或任选取代的碳环或杂环，或 -NR18R19 其中 R18 和 R19 = H、任选取代的烷基或任选取代的碳环或杂环，或任选取代的碳环或杂环。
• Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
  申请人：Kirin Pharma Kabushiki Kaisha

  公开号：EP2258366B1

  公开（公告）日：2013-04-03
• US7425564B2
  申请人：——

  公开号：US7425564B2

  公开（公告）日：2008-09-16